东方生物(688298)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据东方生物三季报分析:

  盈利能力明显恶化,企业经营效益出现亏损

  成长能力有所削弱,公司规模由扩张变为收缩

  偿债能力维持稳定,短期偿债能力很强

  运营能力明显恶化,流动资产合理利用率大幅下降

  现金流能力有所削弱,现金运营指数低,出现收益质量下降

  财务数据
    截至第三季度实现净利润-0.67亿元,每股收益-0.36元。

    截至第三季度最新股东权益792704.70万元,未分配利润703787.32万元。

    截至第三季度最新总资产916998.57万元,负债124293.88万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入652,171,856.12501,543,883.09376,045,281.028,767,938,106.37
营业总成本718,719,790.87457,566,614.1424,274,588.635,068,042,781.38
营业利润-44,437,855.4360,731,225.57-1,445,689.022,528,210,100.3
利润总额-46,240,019.259,216,651.82-37,655,036.312,470,752,364.82
净利润-67,266,359.1937,946,328.87-46,412,8772,097,431,236.78
其他综合收益24,878,026.6628,919,674.68-13,260,781.2540,989,801.51
综合收益总额-42,388,332.5366,866,003.55-59,673,658.252,138,421,038.29
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计6,702,004,059.77,323,188,068.498,283,861,497.838,747,481,069.59
非流动资产合计2,467,981,665.792,388,268,354.312,257,859,606.841,956,258,356.4
资产总计9,169,985,725.499,711,456,422.810,541,721,104.6710,703,739,425.99
流动负债合计847,846,850.71,257,114,231.61,830,276,250.92,278,480,631.04
非流动负债合计395,091,902.52397,245,312.36446,288,323.45102,264,515.38
负债合计1,242,938,753.221,654,359,543.962,276,564,574.352,380,745,146.42
归属于母公司股东权益合计7,779,796,043.047,891,029,258.288,099,040,752.048,162,845,699.44
股东权益合计7,927,046,972.278,057,096,878.848,265,156,530.328,322,994,279.57
负债和股东权益合计9,169,985,725.499,711,456,422.810,541,721,104.6710,703,739,425.99
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计728,268,484.72506,563,103.93235,205,118.3610,798,602,216.28
经营活动现金流出小计2,347,943,587.961,693,607,023.38966,768,9857,802,677,725.05
经营活动产生的现金流量净额-1,619,675,103.24-1,187,043,919.45-731,563,866.642,995,924,491.23
投资活动现金流入小计537,864,910.81378,582,682.54224,196,215.58696,488,033.34
投资活动现金流出小计759,675,964.56532,042,816.89281,015,364.463,072,188,167.33
投资活动产生的现金流量净额-221,811,053.75-153,460,134.35-56,819,148.88-2,375,700,133.99
筹资活动现金流入小计701,000,000500,000,000500,000,00050,000,000
筹资活动现金流出小计665,677,244.47414,360,990.851,783,819.4748,247,622.78
筹资活动产生的现金流量净额35,322,755.5385,639,009.15498,216,180.6-698,247,622.78
汇率变动对现金及现金等价物的影响94,542,948.62131,790,944.6-37,211,732.53536,645,036.51
现金及现金等价物净增加额-1,711,620,452.84-1,123,074,100.05-327,378,567.45458,621,770.97
期末现金及现金等价物余额4,844,939,391.445,433,485,744.236,229,181,276.836,556,559,844.28
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润-0.67亿元,每股收益-0.36元。

    截至第三季度最新股东权益792704.70万元,未分配利润703787.32万元。

    截至第三季度最新总资产916998.57万元,负债124293.88万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入652,171,856.12501,543,883.09376,045,281.028,767,938,106.37
营业总成本718,719,790.87457,566,614.1424,274,588.635,068,042,781.38
营业利润-44,437,855.4360,731,225.57-1,445,689.022,528,210,100.3
利润总额-46,240,019.259,216,651.82-37,655,036.312,470,752,364.82
净利润-67,266,359.1937,946,328.87-46,412,8772,097,431,236.78
其他综合收益24,878,026.6628,919,674.68-13,260,781.2540,989,801.51
综合收益总额-42,388,332.5366,866,003.55-59,673,658.252,138,421,038.29
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计6,702,004,059.77,323,188,068.498,283,861,497.838,747,481,069.59
非流动资产合计2,467,981,665.792,388,268,354.312,257,859,606.841,956,258,356.4
资产总计9,169,985,725.499,711,456,422.810,541,721,104.6710,703,739,425.99
流动负债合计847,846,850.71,257,114,231.61,830,276,250.92,278,480,631.04
非流动负债合计395,091,902.52397,245,312.36446,288,323.45102,264,515.38
负债合计1,242,938,753.221,654,359,543.962,276,564,574.352,380,745,146.42
归属于母公司股东权益合计7,779,796,043.047,891,029,258.288,099,040,752.048,162,845,699.44
股东权益合计7,927,046,972.278,057,096,878.848,265,156,530.328,322,994,279.57
负债和股东权益合计9,169,985,725.499,711,456,422.810,541,721,104.6710,703,739,425.99
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计728,268,484.72506,563,103.93235,205,118.3610,798,602,216.28
经营活动现金流出小计2,347,943,587.961,693,607,023.38966,768,9857,802,677,725.05
经营活动产生的现金流量净额-1,619,675,103.24-1,187,043,919.45-731,563,866.642,995,924,491.23
投资活动现金流入小计537,864,910.81378,582,682.54224,196,215.58696,488,033.34
投资活动现金流出小计759,675,964.56532,042,816.89281,015,364.463,072,188,167.33
投资活动产生的现金流量净额-221,811,053.75-153,460,134.35-56,819,148.88-2,375,700,133.99
筹资活动现金流入小计701,000,000500,000,000500,000,00050,000,000
筹资活动现金流出小计665,677,244.47414,360,990.851,783,819.4748,247,622.78
筹资活动产生的现金流量净额35,322,755.5385,639,009.15498,216,180.6-698,247,622.78
汇率变动对现金及现金等价物的影响94,542,948.62131,790,944.6-37,211,732.53536,645,036.51
现金及现金等价物净增加额-1,711,620,452.84-1,123,074,100.05-327,378,567.45458,621,770.97
期末现金及现金等价物余额4,844,939,391.445,433,485,744.236,229,181,276.836,556,559,844.28
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
安吉福浪莱进出口贸易有限公司3931.2019.500.00
Fangs Holdings Limited Liability Company3780.0018.750.00
安吉涌威创业投资合伙企业(有限合伙)2078.5810.310.00
香港中央结算有限公司878.974.3673.26
中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金329.841.6434.17
中国工商银行股份有限公司-融通健康产业灵活配置混合型证券投资基金140.000.69-100.00
中信信托有限责任公司-中信信托睿郡金融投资集合资金信托计划90.150.4530.20
上海睿郡资产管理有限公司-睿郡11号私募证券投资基金79.260.3979.26
陈根财73.840.3773.84
上海睿郡资产管理有限公司-睿郡5号私募证券投资基金72.100.3610.58
  主力控盘
  公司简介
东方生物 所属地域: 浙江省 涉及概念: 抗原检测,猴痘概念,人民币贬值受益,肝炎概念,沪股通,新冠检测,医疗器械概念,流感,融资融券
主营业务: 基因制品、生物制品研究、开发、生产;第二、三类6840体外诊断试剂及第二类6840临床检验分析仪器生产;医用塑料包装材料加工、销售,模具加工、销售;销售本公司产品。(不涉及《外商投资产业指导目录》限制类、禁止类项目)(涉及许可证或专项审批的凭许可证或待审批后经营)(依法须经批准的项目,经相关部门批准后方可开展经营活动)
上市日期: 2020-02-05 每股净资产: 38.59元 每股收益: -0.36元 净利润: -0.72亿元 净利润增长率: -102.37%
营业收入: 6.52亿元 每股现金流: -8.03元 每股公积金: 2.00元 每股未分配利润: 34.91元 总股本: 1.68亿 流通股: 1.68亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心